Call +44 (0)1904 798634 or +44 (0)7550 079918

Leading provider of life science market reports and research services

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

Be the first to review this product

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

Summary

Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis typically affecting the large joints,...
You can choose to pay by purchase order during checkout

Availability: In stock

$10,995.00

* Required Fields

You can choose to pay by purchase order during checkout
GlobalData.

Digital downloads direct to your inbox within 24 hours.

First class customer service from our team of experts.

Pay by credit card or request an invoice

Product Description

Details

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

Summary

Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis typically affecting the large joints, especially those of the lower extremities and distal joints of the fingers and toes as well as the back and sacroiliac joints of the pelvis. In approximately 80% of PsA patients, skin lesions of psoriasis (PsO), an immune-mediated skin disease, manifest prior to the development of PsA, typically by five to 10 years. PsA most commonly develops between the ages of 30 and 50 and affects men and women equally. Although, early diagnosis and intervention are key in preventing irreversible joint damage, many PsA patients are undiagnosed and go untreated for months or years.

GlobalData projects the PsA market in 7MM to experience strong growth during the forecast period at a CAGR of 10.74%. By the forecast's end in 2025, sales will increase to over $12.58 billion from $4.53 billion in 2015. This growth will be driven primarily by the increase in diagnosed prevalent cases from 1,044,022 in 2015 to 1,520,471 in 2025. Further, the launch of the IL-17 inhibitors, including Novartis' Cosentyx, Eli Lilly's Taltz, and AstraZeneca's Lumicef, as well as the launch of Celgene's oral therapy Otezla, will expand the treatment armamentarium for PsA driving growth in the market.

Highlights

Key Questions Answered

- How large an impact will biosimilars have on the PsA market? What do dermatologists, rheumatologists, and key opinion leaders across the 7MM think about the evolving treatment landscape?
- What opportunities remain in the market for new product entrants?
- What are the most promising late-stage pipeline drugs and how will their launch shape the future treatment landscape in the PsA market?
- According to KOLs, what are the most important unmet needs in PsA? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2025?
- What clinical and commercial factors are likely to affect uptake of PsA therapies in the US, 5EU, and Japan?

Key Findings

- The PsA market is currently very dynamic, with effective biologic therapies recently approved, including interleukin-17 (IL-17) inhibitors - Cosentyx, Taltz, and Lumicef - and oral phosphodiesterase-4 (PDE4) - Otezla.
- Novel biologic therapies will challenge the current anti-TNF biologics in an attempt to dislodge their stronghold, if their safety and efficacy profiles are proven once they enter the market.
- The impending patent cliff for biologics will allow for the emergence of biosimilars to all the marketed biologic brands. Patent expiries take place during the forecast period for the current market leaders such as Johnson & Johnson's Remicade (infliximab), AbbVie's Humira (adalimumab), Amgen's Enbrel (etanercept) and Johnson & Johnson's Stelara (ustekinumab).
- The drivers for market growth will include the increasing diagnosis rate as well as the recent approval of novel therapies. The main challenge for individual drugs will be to distinguish themselves in a crowded marketplace, comprising a highly diversified field of therapies, with existing drugs struggling to increase their patient share.

Scope

- Overview of PsA, including epidemiology, etiology, pathophysiology, symptoms and country-specific diagnosis and treatment recommendations.
- Annualized PsA market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the PsA market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of novel products- including promising IL-17 inhibitors - and biosimilars - such as Celltrion's Hospira, Sandoz's Erelzi, Biogen/Samsung Bioepies' Flixabi and Benepali, and Amgen's Amjevita.
- Analysis of the current and future market competition in the global PsA market (7MM). Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Psoriasis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Psoriasis market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global PsA market from 2015-2025.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Additional Information

Additional Information

Publisher name GlobalData.
Format PDF
Page count 235
Publication date 1 Dec 2016
Table of contents 1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 15
1.2 List of Figures 18
2 Introduction 20
2.1 Catalyst 20
2.2 Related Reports 20
2.3 Upcoming Related Reports 21
3 Disease Overview 22
3.1 Etiology and Pathophysiology 22
3.1.1 Etiology 22
3.1.2 Pathophysiology 24
3.2 Symptoms 26
3.3 Quality of Life 27
4 Epidemiology 28
4.1 Disease Background 28
4.2 Risk Factors and Comorbidities 30
4.3 Global Trends 31
4.4 Forecast Methodology 32
4.4.1 Sources Used 32
4.4.2 Forecast Assumptions and Methods 33
4.4.3 Sources Not Used 40
4.5 Epidemiological Forecast for PsA (2015-2025) 41
4.5.1 Diagnosed Prevalent Cases of PsA 41
4.5.2 Age-Specific Diagnosed Prevalent Cases of PsA 43
4.5.3 Sex-Specific Diagnosed Prevalent Cases of PsA 45
4.5.4 Age-Standardized Diagnosed Prevalence of PsA 47
4.5.5 Diagnosed Prevalent Cases by Type 49
4.5.6 Diagnosed Prevalent Cases by Joint Involvement 50
4.6 Alternative Forecast of Diagnosed Prevalent Cases of PsA 50
4.7 Discussion 52
4.7.1 Epidemiological Forecast Insight 52
4.7.2 Limitations of the Analysis 53
4.7.3 Strengths of the Analysis 54
5 Disease Management 56
5.1 Diagnosis and Treatment Overview 56
5.1.1 Diagnosis 56
5.1.2 Disease Activity 58
5.1.3 Treatment Guidelines and Leading Prescribed Drugs 59
5.1.4 Clinical Practice 68
5.2 US 70
5.3 5EU 71
5.4 Japan 74
6 Competitive Assessment 76
6.1 Overview 76
6.2 Product Profiles - Major Brands 77
6.2.1 Enbrel (etanercept) 77
6.2.2 Humira (adalimumab) 81
6.2.3 Simponi (golimumab) 85
6.2.4 Remicade (infliximab) 89
6.2.5 Cimzia (certolizumab pegol) 94
6.2.6 Cosentyx (secukizumab) 98
6.2.7 Lumicef (brodalumab) 102
6.2.8 Taltz (ixekizumab) 106
6.2.9 Stelara (ustekinumab) 109
6.2.10 Otezla (apremilast) 113
6.3 Other Therapeutic Classes 117
7 Unmet Needs and Opportunities 118
7.1 Overview 118
7.2 Increased Awareness Among Dermatologists and Primary Care Physicians 119
7.2.1 Unmet Need 119
7.2.2 Gap Analysis 120
7.2.3 Opportunity 121
7.3 Early Diagnosis and Treatment 122
7.3.1 Unmet Need 122
7.3.2 Gap Analysis 122
7.3.3 Opportunity 123
7.4 Improved Drug Safety and Efficacy Profiles 123
7.4.1 Unmet Need 123
7.4.2 Gap Analysis 125
7.4.3 Opportunity 126
7.5 Development of Cost-Effective Therapies 127
7.5.1 Unmet Need 127
7.5.2 Gap Analysis 128
7.5.3 Opportunity 129
8 Pipeline Assessment 130
8.1 Overview 130
8.2 Clinical Trial Mapping 130
8.2.1 Clinical Trials by Class 130
8.3 Promising Drugs in Clinical Development 131
8.3.1 Xeljanz (tofacitinib) 134
8.3.2 Orencia (abatacept) 140
8.3.3 Clazakizumab 146
8.4 Other Drugs in Development 151
8.5 Biosimilars 153
8.5.1 Introduction 153
8.5.2 Biosimilars Versus Branded Biologics in Key Autoimmune Diseases 154
8.5.3 Biosimilars in the Immunology Community 156
8.5.4 By the Numbers: Biosimilars in Development 156
8.5.5 The Impact of Biosimilars Will Be Felt Throughout the Pharmaceutical Industry 162
8.5.6 Uptake of Biosimilars is Expected to Vary by Market 162
9 Current and Future Players 165
9.1 Overview 165
9.2 Trends in Corporate Strategy 168
9.3 Company Profiles 169
9.3.1 Amgen 169
9.3.2 AbbVie 170
9.3.3 Johnson & Johnson 171
9.3.4 UCB 173
9.3.5 Novartis 174
9.3.6 Celgene 175
9.3.7 Pfizer 176
9.3.8 Bristol-Myers Squibb 177
9.3.9 AstraZeneca 178
9.3.10 Eli Lilly 179
9.3.11 Alder 180
10 Market Outlook 182
10.1 Global Markets 182
10.1.1 Forecast 182
10.1.2 Drivers and Barriers - Global Issues 185
10.2 US 187
10.2.1 Forecast 187
10.2.2 Key Events 191
10.2.3 Drivers and Barriers 192
10.3 5EU 192
10.3.1 Forecast 192
10.3.2 Key Events 196
10.3.3 Drivers and Barriers 197
10.4 Japan 197
10.4.1 Forecast 197
10.4.2 Key Events 200
10.4.3 Drivers and Barriers 201
11 Appendix 202
11.1 Bibliography 202
11.2 Abbreviations 213
11.3 Methodology 220
11.4 Forecasting Methodology 220
11.4.1 Diagnosed Psoriatic Arthritis Patients 220
11.4.2 Percent Drug-Treated Patients 220
11.4.3 Drugs Included in Each Therapeutic Class 221
11.4.4 Launch and Patent Expiry Dates 221
11.4.5 General Pricing Assumptions 222
11.4.6 Individual Drug Assumptions 223
11.4.7 Generic Erosion 227
11.4.8 Pricing of Pipeline Agents 228
11.5 Primary Research - Key Opinion Leaders Interviewed for This Report 229
11.6 Primary Research - Prescriber Survey 231
11.7 About the Authors 232
11.7.1 Analyst 232
11.7.2 Therapy Area Director 232
11.7.3 Epidemiologist 232
11.7.4 Global Director of Therapy Analysis and Epidemiology 233
11.8 About GlobalData 234
11.9 Disclaimer 234

Reviews

Write Your Own Review

Only registered users can write reviews. Please, log in or register

Product Tags

Product Tags

Use spaces to separate tags. Use single quotes (') for phrases.